Suppr超能文献

非酒精性脂肪性肝病、代谢风险因素与肝细胞癌:一个悬而未决的问题。

Nonalcoholic fatty liver disease, metabolic risk factors, and hepatocellular carcinoma: an open question.

作者信息

Streba Letiția Adela Maria, Vere Cristin Constantin, Rogoveanu Ion, Streba Costin Teodor

机构信息

Letiția Adela Maria Streba, Internal Medicine, Medical Semiology, University of Medicine and Pharmacy of Craiova, 200639 Craiova, Romania.

出版信息

World J Gastroenterol. 2015 Apr 14;21(14):4103-10. doi: 10.3748/wjg.v21.i14.4103.

Abstract

Non-alcoholic liver disease (NAFLD) defines liver abnormalities ranging from simple steatosis to nonalcoholic steatohepatitis with or without cirrhosis development, occurring in the absence of significant alcohol consumption, use of teratogenic medication, or hereditary disorders. The association between NAFLD and metabolic syndrome is well documented and widely recognized. Obesity, type 2 diabetes mellitus (T2DM), and dyslipidemia are the most common metabolic risk factors associated with NAFLD. Among the components of metabolic syndrome, current evidence strongly indicates obesity and diabetes as hepatocellular carcinoma (HCC) risk factors. There is also growing evidence that suggests an increased risk of HCC in NAFLD patients, even surpassing other etiologies in some high-income countries. Epidemiologic data demonstrate a parallel rise in prevalence of obesity, diabetes, NAFLD, and HCC. As obesity and its related diseases have steadily afflicted larger populations, HCC incidence is expected to increase in the future. Pathophysiologic mechanisms that underlie NAFLD development and subsequent progression to nonalcoholic steatohepatitis and cirrhosis (insulin resistance and hyperinsulinemia, oxidative stress, hepatic stellate cell activation, cytokine/adipocytokine signaling pathways, and genetic and environmental factors) appear to play a significant role in the development of NAFLD-related HCC. However, a comprehensive view of molecular mechanisms linking obesity, T2DM, and NAFLD-related HCC, as well as the exact sequence of molecular events, is still not understood in its entirety. Good-quality data are still necessary, and efforts should continue towards better understanding the underlying carcinogenic mechanisms of NAFLD-related HCC. In this paper, we aimed to centralize the most important links supporting these relationships, focusing on obesity, T2DM, and NAFLD-related HCC, as well as point out the major gaps in knowledge regarding the underlying molecular mechanisms behind them.

摘要

非酒精性肝病(NAFLD)指的是在无大量饮酒、使用致畸药物或遗传性疾病的情况下,出现的从单纯性脂肪变性到非酒精性脂肪性肝炎(伴或不伴有肝硬化发展)的肝脏异常情况。NAFLD与代谢综合征之间的关联已有充分记录且广为人知。肥胖、2型糖尿病(T2DM)和血脂异常是与NAFLD相关的最常见代谢风险因素。在代谢综合征的各个组成部分中,目前的证据有力地表明肥胖和糖尿病是肝细胞癌(HCC)的风险因素。也有越来越多的证据表明,NAFLD患者患HCC 的风险增加,在一些高收入国家甚至超过其他病因。流行病学数据显示肥胖、糖尿病、NAFLD和HCC的患病率呈平行上升趋势。随着肥胖及其相关疾病不断困扰着越来越多的人群,预计未来HCC的发病率将会增加。NAFLD发展以及随后进展为非酒精性脂肪性肝炎和肝硬化的病理生理机制(胰岛素抵抗和高胰岛素血症、氧化应激、肝星状细胞激活、细胞因子/脂肪细胞因子信号通路以及遗传和环境因素)似乎在NAFLD相关HCC的发生中起重要作用。然而,肥胖、T2DM和NAFLD相关HCC之间分子机制的全面观点,以及分子事件的确切顺序,仍未完全明了。高质量的数据仍然是必要的,应继续努力更好地理解NAFLD相关HCC的潜在致癌机制。在本文中,我们旨在集中阐述支持这些关系的最重要联系,重点关注肥胖、T2DM和NAFLD相关HCC,并指出关于其潜在分子机制的主要知识空白。

相似文献

1
Nonalcoholic fatty liver disease, metabolic risk factors, and hepatocellular carcinoma: an open question.
World J Gastroenterol. 2015 Apr 14;21(14):4103-10. doi: 10.3748/wjg.v21.i14.4103.
3
Nonalcoholic Fatty Liver Disease/Nonalcoholic Steatohepatitis and Hepatocellular Carcinoma.
Clin Liver Dis. 2018 Feb;22(1):201-211. doi: 10.1016/j.cld.2017.08.014.
4
The story of HCC in NAFLD: from epidemiology, across pathogenesis, to prevention and treatment.
Liver Int. 2016 Mar;36(3):317-24. doi: 10.1111/liv.13031. Epub 2015 Dec 25.
5
Nonalcoholic Fatty Liver Disease-Related Hepatocellular Carcinoma: A Problem of Growing Magnitude.
Semin Liver Dis. 2015 Aug;35(3):304-17. doi: 10.1055/s-0035-1562949. Epub 2015 Sep 17.
6
Nonalcoholic Fatty liver disease, diabetes, obesity, and hepatocellular carcinoma.
Clin Liver Dis. 2015 May;19(2):361-79. doi: 10.1016/j.cld.2015.01.012. Epub 2015 Mar 12.
7
Trends in hepatocellular carcinoma due to non-alcoholic fatty liver disease.
Expert Rev Gastroenterol Hepatol. 2019 Feb;13(2):179-187. doi: 10.1080/17474124.2019.1549989. Epub 2018 Dec 29.
8
Liver Cancer: Connections with Obesity, Fatty Liver, and Cirrhosis.
Annu Rev Med. 2016;67:103-17. doi: 10.1146/annurev-med-090514-013832. Epub 2015 Oct 14.
10
Epidemiology and Natural History of Nonalcoholic Fatty Liver Disease.
Semin Liver Dis. 2015 Aug;35(3):221-35. doi: 10.1055/s-0035-1562943. Epub 2015 Sep 17.

引用本文的文献

1
Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD): the interplay of gut microbiome, insulin resistance, and diabetes.
Front Med (Lausanne). 2025 Aug 14;12:1618275. doi: 10.3389/fmed.2025.1618275. eCollection 2025.
3
Hepatocellular carcinoma: pathogenesis, molecular mechanisms, and treatment advances.
Front Oncol. 2025 Apr 8;15:1526206. doi: 10.3389/fonc.2025.1526206. eCollection 2025.
4
Hepatic IR and IGF1R signaling govern distinct metabolic and carcinogenic processes upon PTEN deficiency in the liver.
JHEP Rep. 2024 Dec 19;7(4):101305. doi: 10.1016/j.jhepr.2024.101305. eCollection 2025 Apr.
5
Targeting cGAS-STING: modulating the immune landscape of hepatic diseases.
Front Immunol. 2025 Mar 3;16:1498323. doi: 10.3389/fimmu.2025.1498323. eCollection 2025.
6
Nonalcoholic fatty liver disease and colorectal cancer: a two-sample bidirectional Mendelian randomization analysis.
Eur J Gastroenterol Hepatol. 2024 Dec 1;36(12):1447-1452. doi: 10.1097/MEG.0000000000002859. Epub 2024 Oct 30.
8
MASLD-Related Hepatocarcinoma: Special Features and Challenges.
J Clin Med. 2024 Aug 8;13(16):4657. doi: 10.3390/jcm13164657.

本文引用的文献

1
Targeting the insulin-like growth factor pathway in hepatocellular carcinoma.
World J Hepatol. 2014 Oct 27;6(10):716-37. doi: 10.4254/wjh.v6.i10.716.
2
Hepatocellular carcinoma in nonalcoholic fatty liver: role of environmental and genetic factors.
World J Gastroenterol. 2014 Sep 28;20(36):12945-55. doi: 10.3748/wjg.v20.i36.12945.
3
Could metabolic syndrome lead to hepatocarcinoma via non-alcoholic fatty liver disease?
World J Gastroenterol. 2014 Jul 28;20(28):9217-28. doi: 10.3748/wjg.v20.i28.9217.
5
Obesity and non-alcoholic fatty liver disease: Disparate associations among Asian populations.
World J Hepatol. 2014 May 27;6(5):263-73. doi: 10.4254/wjh.v6.i5.263.
8
What about non-alcoholic fatty liver disease as a new criterion to define metabolic syndrome?
World J Gastroenterol. 2013 Jun 14;19(22):3375-84. doi: 10.3748/wjg.v19.i22.3375.
9
From NAFLD in clinical practice to answers from guidelines.
J Hepatol. 2013 Oct;59(4):859-71. doi: 10.1016/j.jhep.2013.05.044. Epub 2013 Jun 7.
10
Obesity-associated oxidative stress: strategies finalized to improve redox state.
Int J Mol Sci. 2013 May 21;14(5):10497-538. doi: 10.3390/ijms140510497.

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验